Skip to main content
Home

Top menu infoNTD

  • About InfoNTD
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoNTD

  • NTDs [14]
    • Buruli ulcer
    • Chagas disease
    • Dracunculiasis
    • Human African trypanosomiasis
    • Leishmaniasis
    • Leprosy
    • Lymphatic filariasis
    • Mycetoma
    • Onchocerciasis
    • Schistosomiasis
    • Snakebite envenoming
    • Soil-transmitted helminthiasis
    • Trachoma
    • Yaws
  • Cross-cutting issues [13]
    • Data management & analysis [3]
      • Data collection and reporting
      • Mapping
      • Indicators
    • Integrated wound management
    • Capacity strengthening
    • Management of disease complications [2]
      • Medical management
      • Surgical management
    • Prevention of disability [3]
      • Eye care
      • Self-care
      • Disability measurement
    • Physical rehabilitation [3]
      • Physical therapy
      • Orthopaedic footwear
      • Protheses, walking devices and wheelchairs
    • Stigma and mental wellbeing [1]
      • Mental wellbeing project mapping
    • Inclusion [2]
      • Community-based rehabilitation
      • Gender
    • WASH and NTDs
    • Health systems factors
    • Skin-NTDs
    • Preventive Chemotherapy
    • Health education
  • Toolkits [5]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • Perception Study Toolkit (PST)
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • NTD Toolbox
    • CBM's Community Mental Health Good Practice Guides
  • Online courses

Top menu infoNTD

  • About InfoNTD
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Barriers and Enablers to Health-Seeking for People Affected by Severe Stigmatising Skin Diseases (SSSDs): A Scoping Review

McCollum R, Berrian H, Theobald S, et al. MDPI AG. Social Sciences. 2022; 11 (8) : 332.
Download PDF
Publication

Effect of a Community-Based Holistic Care Package on Physical and Psychosocial Outcomes in People with Lower Limb Disorder Caused by Lymphatic Filariasis, Podoconiosis, and Leprosy in Ethiopia: Results from the EnDPoINT Pilot Cohort Study.

Dellar R, Ali O, Kinfe M, et al. The American journal of tropical medicine and hygiene. 2022;
Publication

Housing Risk Factors of Four Tropical Neglected Diseases: A Brief Review of the Recent Literature

Chastonay AHM, Chastonay OJ. MDPI AG. Tropical Medicine and Infectious Disease. 2022; 7 (7) : 143.
Download PDF
Publication

Step towards elimination of Wuchereria bancrofti in Southwest Tanzania 10 years after mass drug administration with Albendazole and Ivermectin

Mnkai J, Marandu TF, Mhidze J, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2022; 16 (7) : e0010044.
Download PDF
Publication

Bacterial diversity significantly reduces toward the late stages among filarial lymphedema patients in the Ahanta West District of Ghana: A cross‐sectional study

Asiedu SO, Kini P, Aglomasa BC, et al. Wiley. Health Science Reports. 2022;
Download PDF
Publication

Sustaining communicable disease elimination efforts in the Americas in the wake of COVID-19

Espinal MA, Alonso M, Sereno L, et al. Elsevier BV. The Lancet Regional Health - Americas. 2022;
Download PDF
Publication

A mixed-methods exploration into the resilience of community drug distributors conducting mass drug administration for preventive chemotherapy of lymphatic filariasis and onchocerciasis in Côte d’Ivoire and Uganda

Dilliott D, Addiss D, Thickstun C, et al. Public Library of Science (PLoS). PLOS Global Public Health. 2022; 2 (7) : e0000700.
Download PDF
Publication

Historical overview and geographical distribution of neglected tropical diseases amenable to preventive chemotherapy in the Republic of the Congo: A systematic review

Ngatse JA, Ndziessi G, Missamou F, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2022; 16 (7) : e0010560.
Download PDF
Publication

Mass drug administration for lymphatic filariasis elimination amidst COVID-19 pandemic in Odisha, India: A step towards achieving SDG-3

Sinha A, Mohapatra S, Mohanty S, et al. SAGE Publications. Tropical Doctor. 2022;
Download PDF
Publication

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.

Sabesan S, Krishnamoorthy K, Hoti S, et al. The Indian journal of medical research. 2022;

Pagination

  • Previous page ‹‹
  • Page 45
  • Next page ››
Subscribe to Lymphatic filariasis (Elephantiasis)

Quick Links

  • Toolbox
  • Publications
  • Organizations
  • NTDs

Support

  • Contact
  • FAQ
  • Privacy statement

Contact us infoNTD

info@InfoNTD.org

(+31) 20 595 0526

     

Stay up to date with the latest developments in NTDs. We share a monthly overview via email showing a selection of the latest NTD publications and tools. 

Subscribe

Related websites NTD:

  • Infolep

© 2025 InfoNTD